Mounjaro and asthma: can you use tirzepatide if you have a respiratory condition?

Is there anything in Mounjaro's licensed guidance that flags asthma as a concern?

The short answer is no. Reviewing the tirzepatide SmPC and the NHS medicines page for tirzepatide, asthma does not appear in the list of contraindications, and it is not singled out as a condition requiring special caution in the way that, say, a history of pancreatitis or medullary thyroid carcinoma would be. That is reassuring as far as it goes.

It does not mean asthma is irrelevant to the consultation, though. A prescriber reviewing your case will want to know which medicines you take, including inhalers. Some inhaled corticosteroids can affect weight, and certain oral medications used in severe or difficult-to-control asthma may interact with how your body processes other treatments. These are nuances worth discussing openly rather than assuming they cancel each other out.

People with asthma who also meet the eligibility criteria for Mounjaro (a body mass index of 30 or above, or 27 or above with a weight-related health condition) have been prescribed it in clinical practice without asthma being a barrier. The prescriber's job is to weigh your individual circumstances, not apply a blanket rule. Our clinical team takes exactly this approach on every consultation.

Could Mounjaro's side effects affect your breathing or asthma symptoms?

This is a question our prescribers hear most weeks, and it deserves a straightforward answer. Mounjaro's most common side effects are gastrointestinal: nausea, acid reflux, indigestion and bloating are frequently reported, particularly in the first few weeks of treatment or after a dose increase. For most people these settle as the body adjusts.

For someone with asthma, reflux deserves a specific mention. Gastro-oesophageal reflux can irritate the airways and is a recognised trigger for asthma symptoms in some patients. If you already manage reflux alongside asthma, it is worth telling your prescriber before starting tirzepatide, so they can factor that into your care plan. It does not rule out treatment, but it does shape the conversation.

There is no evidence that tirzepatide causes bronchospasm or directly narrows the airways. The respiratory side effects noted in trial data are uncommon and not mechanistically linked to airway constriction. The MHRA's Drug Safety Updates for GLP-1 medicines have focused primarily on pancreatitis and related gastrointestinal events, asthma has not featured as an emerging signal. Keep using your inhalers as prescribed throughout treatment and tell your GP or asthma nurse if your symptoms change.

Does losing weight with Mounjaro actually help asthma control?

There is a strong biological reason to think it can. Obesity and asthma interact in several ways: excess abdominal weight limits diaphragm movement, reduces lung volumes and increases airway resistance. Fat tissue also produces pro-inflammatory mediators that can amplify airway inflammation independently of allergen exposure. This is sometimes described as obesity-related asthma, and it tends to respond less well to standard inhaled corticosteroids than classic atopic asthma.

Clinical evidence consistently shows that meaningful weight loss improves asthma outcomes: better symptom control, reduced rescue inhaler use and improved lung function scores. In the SURMOUNT-1 trial, participants using tirzepatide at the highest dose lost around 20–21% of body weight on average over 72 weeks, with thousands of adults enrolled across the programme. For someone with obesity-related asthma, that scale of weight reduction could be clinically significant for their respiratory health, not just their weight.

This does not mean Mounjaro is prescribed for asthma, it is licensed for weight management, full stop. But it does mean that for people with both conditions, treating obesity may carry respiratory benefits that go beyond what the scales show. You can read more about how tirzepatide interacts with asthma on our dedicated page, or explore how obesity and other health conditions interact with weight management options on our treatment overview.

How does asthma fit into the Mounjaro eligibility and consultation process?

Asthma itself is not one of the named weight-related comorbidities in the tirzepatide licence, conditions like high blood pressure, dyslipidaemia, obstructive sleep apnoea, type 2 diabetes and cardiovascular disease appear in that list. So asthma alone at a BMI of 27–29.9 would not, strictly speaking, satisfy the licensing threshold. Obstructive sleep apnoea is distinct from asthma but does appear on that list, and some people have both; a prescriber can assess this properly.

If your BMI is 30 or above, asthma is not a barrier to eligibility, and it is worth noting that whether Mounjaro is suitable if you have asthma depends on your complete health profile, not a single variable. Conditions like polycystic ovary syndrome or kidney conditions also require the same kind of individual assessment.

At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber, a real clinician reads your answers the same day. Treatment is not approved by an algorithm. If you have questions about your inhalers, current asthma control or any other aspect of your health, the consultation is the place to raise them. For further reading on cost and what private treatment involves, our Mounjaro price comparison page breaks down what to look for. When you are ready, start your free consultation and let a prescriber assess your individual picture properly.